ADRB2 and prostate carcinoma: Studies by some scholars have shown that using adrenaline to activate ADRB2 delays the apoptosis of cancer cells in prostate cancer, thus increasing the resistance to cytotoxic drugs, and proved that this anti-apoptotic effect is triggered by the ADRB2-PKA-MCL1 signaling pathway (18).